Originally available in injection form, GLP-1 drugs are now available as oral pills, providing patients with a choice between two delivery methods
Safety concerns : Important risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease, dehydration leading to acute kidney injury, hypoglycaemia (when used with insulin or sulfonylureas), and potential worsening of diabetic retinopathy with rapid glycaemic improvement
Reproduced from Mozaffarian et al
Research indicates that stopping or interrupting obesity treatments, particularly weight-loss medications like GLP-1 drugs, frequently results in a rapid regain of lost weight
Tirzepatide overcomes these limitations by simultaneously activating both GIPR and GLP-1R, thereby harnessing their complementary mechanisms of action [25]
Tirzepatide is a peptide, which is essentially a short chain of amino acids